

Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Original) A pharmaceutical composition comprising an anti-FAM3D antibody as an active ingredient, wherein the compound is for damaging an FAM3D-expressing cell using antibody effector function.
2. (Original) The pharmaceutical composition of claim 1, wherein the FAM3D-expressing cell is a lung cancer cell.
3. (Original) The pharmaceutical composition of claim 1, wherein the anti-FAM3D antibody is a monoclonal antibody.
4. (Original) The pharmaceutical composition of claim 1, wherein the antibody effector function is either antibody-dependent cytotoxicity or complement-dependent cytotoxicity, or both.
5. (Original) A method for damaging an FAM3D-expressing cell, comprising the steps of:
 - a) contacting the FAM3D-expressing cell with an anti-FAM3D antibody, and
 - b) damaging the FAM3D-expressing cell with the effector function of the antibody that has bound to the cell.
6. (Original) An immunogenic composition for inducing an antibody that comprises an effector function against an FAM3D-expressing cell, wherein the composition comprises, as an active ingredient, FAM3D, an immunologically active fragment thereof, or a DNA that can express them.

7. (Original) A method for inducing an antibody that comprises an effector function against an FAM3D-expressing cell, wherein the method comprises administering FAM3D, an immunologically active fragment thereof, or a cell or a DNA that can express them.